Shruti Chaturvedi
Overview
Explore the profile of Shruti Chaturvedi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1307
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sullivan S, Chaturvedi S, Gautam P, Arnaud A
J Manag Care Spec Pharm
. 2025 Feb;
31(3):277-288.
PMID: 40021467
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administration...
2.
Mahmoud A, Mostafa M, Abdelhay A, Abou-Ismail M, Chaturvedi S
Res Pract Thromb Haemost
. 2025 Jan;
9(1):102654.
PMID: 39830971
Background: The addition of caplacizumab to immune thrombotic thrombocytopenia (iTTP) treatment options has led to a renewed interest in characterizing the epidemiology and risk factors for bleeding in iTTP. Limited...
3.
Sullivan S, Chaturvedi S, Gautam P, Arnaud A
J Manag Care Spec Pharm
. 2024 Dec;
:1-12.
PMID: 39714307
Background: Immune thrombotic thrombocytopenic purpura (iTTP) is a rare, life-threatening thrombotic microangiopathy. Caplacizumab is the only treatment approved by the European Medicines Agency and the US Food and Drug Administration...
4.
Fatola A, Fatola A, Evans M, Brown J, Davis E, Johnson A, et al.
Blood Adv
. 2024 Dec;
9(2):417-424.
PMID: 39626301
Immune thrombotic thrombocytopenic purpura (iTTP) is a chronically relapsing disorder caused by autoantibody-mediated deficiency of ADAMTS13. Rituximab is frequently administered to prevent relapses, but whether the durability of rituximab effect...
5.
Cole M, Ranjan N, Gerber G, Pan X, Flores-Guerrero D, McNamara G, et al.
Blood
. 2024 Oct;
144(24):2528-2545.
PMID: 39357054
Complement-mediated thrombotic microangiopathy (CM-TMA) or hemolytic uremic syndrome, previously identified as atypical hemolytic uremic syndrome, is a TMA characterized by germ line variants or acquired antibodies to complement proteins and...
6.
Story C, Chaturvedi S
Am J Hematol
. 2024 Sep;
100(3):488-489.
PMID: 39329516
The differential diagnosis for secondary hemophagocytic lymphohistiocytosis includes infectious, malignant, and autoimmune causes.
7.
Nester C, Feldman D, Burwick R, Cataland S, Chaturvedi S, Cook H, et al.
Kidney Int
. 2024 Aug;
106(3):326-336.
PMID: 39174192
The term atypical hemolytic uremic syndrome has been in use since the mid-1970s. It was initially used to describe the familial or sporadic form of hemolytic uremic syndrome as opposed...
8.
Cole M, Ranjan N, Gerber G, Pan X, Flores-Guerrero D, Chaturvedi S, et al.
bioRxiv
. 2024 Jun;
PMID: 38854038
Key Points: CM-HUS has a CP stimulus driven by polyreactive IgM, addressing the mystery of why 40% of CM-HUS lack complement specific variantsComplement biosensors and the bioluminescent mHam can be...
9.
Abou-Ismail M, Zhang C, Presson A, Chaturvedi S, Antun A, Farland A, et al.
Res Pract Thromb Haemost
. 2024 Apr;
8(3):102388.
PMID: 38651093
Background: Mortality due to immune-mediated thrombotic thrombocytopenic purpura (iTTP) remains significant. Predicting mortality risk may potentially help individualize treatment. The French Thrombotic Microangiopathy (TMA) Reference Score has not been externally...
10.
Bakow B, Yanek L, Crowther M, Chaturvedi S
Thromb Res
. 2024 Apr;
237:88-93.
PMID: 38569453
Thrombotic antiphospholipid syndrome (TAPS) is characterized by thrombosis and persistently positive tests for antiphospholipid antibodies or lupus anticoagulant (LAC). Triple-positive APS has the highest risk of recurrent thrombosis, but no...